Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 20,000 shares at $35.60 ($712K) on 2022-07-25, disclosed to the SEC on 2022-07-27.
Open-market sale of $712k DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.60 | 19,800 | $705K | 99.0% |
| 2 | $36.15 | 200 | $7K | 1.0% |
| Total | $35.61 avg | 20,000 | $712K | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |